HRP20080359B1 - PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a - Google Patents
PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-aInfo
- Publication number
- HRP20080359B1 HRP20080359B1 HRP20080359AA HRP20080359A HRP20080359B1 HR P20080359 B1 HRP20080359 B1 HR P20080359B1 HR P20080359A A HRP20080359A A HR P20080359AA HR P20080359 A HRP20080359 A HR P20080359A HR P20080359 B1 HRP20080359 B1 HR P20080359B1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- optionally substituted
- alkyloxy
- amino
- nhc
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 3
- -1 cyano, nitro, amino Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
Abstract
Ovaj izum odnosi se na upotrebu spojeva formule (I),njihovih N-oksida, farmaceutski prihvatljivih adicijskih soli, kvaternih amina i njihovih stereokemijski izomernih oblika, u kojoj formuli-a=a-a=a- tvori fenil, piridinil, pirimidinil, piridazinil ili pirazinil s povezanom vinilnom skupinom;n je 0 do 4, i gdje je to moguće 5;Rje vodik, aril, formil, C-alkil karbonil, C-alkil, C-alkiloksikarbonil, supstituirani C-alkil, ili supstituirani C-alkiloksi-C-alkilkarbonil;svaki od Rneovisno predstavlja hidroksi, halogen, prema potrebi supstituirani C-alkil, C-alkenil ili C-alkinil, C-cikloalkil, C-alkiloksi, C-alkiloksi-karbonil, karboksil, cijano, nitro, amino, mono- ili di-(C-alkil)amino, polihalometil, polihalometiloksi, polihalometiltio, -S(=O)R, -NH-S(=O)R, -C(=O)R, -NHC(=O)H, -C(=O)NHNH, -NHC(=O)R, -C=NH) Rili peteročlani heterociklički prsten;p je 1 ili 2;L je prema potrebi supstituirani C-alkil, C-alkenil, C-alkinil, C-cikloalkil; iliL je -X-RgdjeRje prema potrebi supstituirani fenil, piridinil, pirimidinil, pirazinil ili piridazinil;X je -NR-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- ili -S(=O)-;Q je vodik, C-alkil, halogen, polihalo-C-alkil ili prema potrebi supstituirana amino skupina;Y predstavlja hidroksi, halogen, C-cikloalkil, prema potrebi supstituirani C-alkil, C-alkenil ili C-alkinil, C-alkiloksi, C-alkiloksi-karbonil, karboksil, cijano, nitro, amino, mono- ili di (C-alkil) amino, polihalo-metil, polihalometiloksi, polihalometiltio, -S(=O)R, -NH-S(=O)R, -C(=O)R, -NHC(=O)H, -C(-O)NHNH, -NHC(=O)R, -C(=NH)Rili aril;aril je prema potrebi supstituirani fenil;Het je prema potrebi supstituirani heterociklički radikal;za proizvodnju lijeka za liječenje osoba koje pate od infekcije s HIV-om (virus humane imunodeficijencije).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10779298P | 1998-11-10 | 1998-11-10 | |
US14396299P | 1999-07-15 | 1999-07-15 | |
PCT/EP1999/007417 WO2000027825A1 (en) | 1998-11-10 | 1999-09-24 | Hiv replication inhibiting pyrimidines |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20080359A2 HRP20080359A2 (hr) | 2008-12-31 |
HRP20080359B1 true HRP20080359B1 (hr) | 2016-01-01 |
Family
ID=26805159
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20010161AA HRP20010161B9 (hr) | 1998-11-10 | 2001-03-07 | PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a |
HRP20080359AA HRP20080359B1 (hr) | 1998-11-10 | 2008-07-17 | PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20010161AA HRP20010161B9 (hr) | 1998-11-10 | 2001-03-07 | PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a |
Country Status (41)
Country | Link |
---|---|
US (5) | US6878717B2 (hr) |
EP (2) | EP1002795B1 (hr) |
JP (1) | JP3635238B2 (hr) |
KR (1) | KR100658489B1 (hr) |
CN (1) | CN1214013C (hr) |
AP (1) | AP1683A (hr) |
AR (1) | AR024227A1 (hr) |
AT (2) | ATE455107T1 (hr) |
AU (2) | AU762523C (hr) |
BG (1) | BG65103B1 (hr) |
BR (1) | BRPI9915552B8 (hr) |
CA (1) | CA2350801C (hr) |
CY (1) | CY2008021I2 (hr) |
CZ (1) | CZ301367B6 (hr) |
DE (3) | DE69905683T2 (hr) |
DK (1) | DK1002795T3 (hr) |
EA (1) | EA004049B1 (hr) |
EE (1) | EE05086B1 (hr) |
ES (2) | ES2193664T3 (hr) |
FR (1) | FR09C0004I2 (hr) |
HK (2) | HK1025330A1 (hr) |
HR (2) | HRP20010161B9 (hr) |
HU (2) | HU230394B1 (hr) |
ID (1) | ID28376A (hr) |
IL (2) | IL143023A0 (hr) |
LT (1) | LTC1002795I2 (hr) |
LU (1) | LU91528I2 (hr) |
MY (1) | MY121108A (hr) |
NL (1) | NL300373I2 (hr) |
NO (3) | NO318801B1 (hr) |
NZ (1) | NZ511116A (hr) |
OA (1) | OA11674A (hr) |
PL (1) | PL204427B1 (hr) |
PT (1) | PT1002795E (hr) |
SI (1) | SI1002795T1 (hr) |
SK (2) | SK287269B6 (hr) |
TR (1) | TR200101306T2 (hr) |
TW (1) | TWI238161B (hr) |
UA (1) | UA70966C2 (hr) |
WO (1) | WO2000027825A1 (hr) |
ZA (1) | ZA200103769B (hr) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA11674A (en) * | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
EA005423B1 (ru) * | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
JP2003511378A (ja) | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
ES2542326T3 (es) * | 2000-05-08 | 2015-08-04 | Janssen Pharmaceutica Nv | Inhibidores de la replicación del VIH |
DK1282607T3 (en) * | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
EP1337931A4 (en) * | 2000-11-01 | 2005-05-11 | Snapnames Com Inc | DOMAIN NAME ACQUISITION AND MANAGEMENT SYSTEM AND METHOD |
US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
EP2090571B1 (de) * | 2001-10-17 | 2012-05-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
US7183288B2 (en) | 2001-11-01 | 2007-02-27 | Herwig Josephus Margareta Janssen, legal representative | Amide derivatives as glycogen synthase kinase 3-β inhibitors |
EP1448556A1 (en) | 2001-11-01 | 2004-08-25 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
PL212089B1 (pl) | 2002-03-13 | 2012-08-31 | Janssen Pharmaceutica Nv | Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja |
KR20040094672A (ko) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체 |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
WO2003093344A1 (en) * | 2002-05-03 | 2003-11-13 | Janssen Pharmaceutica N.V. | Polymeric microemulsions |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
AR040456A1 (es) | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
CN101481356B (zh) * | 2002-08-09 | 2012-07-11 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
DK1551372T3 (en) * | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
EA200500721A1 (ru) * | 2002-11-28 | 2005-12-29 | Шеринг Акциенгезельшафт | Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств |
EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
MXPA05008368A (es) * | 2003-02-07 | 2005-11-04 | Janssen Pharmaceutica Nv | 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana. |
EP1597237B1 (en) | 2003-02-07 | 2016-07-27 | Janssen Pharmaceutica NV | Pyrimidine derivatives for the prevention of HIV infection |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
WO2005011702A1 (en) * | 2003-07-17 | 2005-02-10 | Tibotec Pharmaceuticals Ltd. | Process for preparing particles containing an antiviral |
CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
WO2005028479A2 (en) * | 2003-09-25 | 2005-03-31 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting purine derivatives |
EP1728186A2 (en) | 2004-03-02 | 2006-12-06 | Virco Bvba | Estimation of clinical cut-offs |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
WO2006010750A1 (en) | 2004-07-28 | 2006-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
RU2401833C2 (ru) | 2004-08-10 | 2010-10-20 | Янссен Фармацевтика Н.В. | Производные 1, 2, 4-триазин-6-она, ингибирующие вич |
TW200626574A (en) * | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-heterocyclyl pyrimidines |
CN101027288B (zh) * | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
BRPI0515935B8 (pt) | 2004-09-30 | 2021-05-25 | Janssen Sciences Ireland Uc | pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica |
BRPI0517272A (pt) | 2004-10-29 | 2008-10-07 | Tibotec Pharm Ltd | derivados de pirimidina bicìclicos de inibição de hiv |
CA2583187A1 (en) * | 2004-11-08 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and etravirine |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
AU2006208778B2 (en) | 2005-01-27 | 2012-08-09 | Janssen Sciences Ireland Uc | HIV inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives |
WO2006087530A1 (en) | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
JP5247154B2 (ja) * | 2005-02-18 | 2013-07-24 | テイボテク・フアーマシユーチカルズ | Hiv阻害性2−(4−シアノフェニルアミノ)ピリミジンオキシド誘導体 |
RU2401261C2 (ru) * | 2005-03-04 | 2010-10-10 | Тиботек Фармасьютикалз Лтд. | Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины |
EP1899323A2 (en) | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
MX2007014881A (es) * | 2005-05-26 | 2008-02-15 | Tibotec Pharm Ltd | Procedimiento para preparar 4-(1,6-dihidro-6-oxo-2-pirimidinil) amino benzonitrilo. |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7754773B2 (en) * | 2005-10-06 | 2010-07-13 | University Of Massachusetts | Composition and synthesis of new reagents for inhibition of HIV replication |
BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
EP1979326B1 (en) | 2006-01-19 | 2012-10-03 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
AU2007206950B2 (en) | 2006-01-19 | 2012-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
DK1981874T3 (da) | 2006-01-19 | 2009-09-28 | Janssen Pharmactuica N V | Aminophenylderivater som nye inhibitorer af histondeacetylase |
CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
EP2004641B1 (en) | 2006-03-30 | 2010-09-29 | Tibotec Pharmaceuticals | Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines |
PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
WO2007141308A1 (en) * | 2006-06-06 | 2007-12-13 | Tibotec Pharmaceuticals Ltd. | Process for preparing spray dried formulations of tmc125 |
CN101677963B (zh) | 2006-06-19 | 2012-05-30 | 奥尔制药公司 | 药物组合物 |
CA2665726C (en) * | 2006-10-11 | 2016-04-19 | Alpharma, Inc. | Pharmaceutical compositions |
EP2104491B1 (en) | 2006-12-06 | 2017-02-22 | Janssen Sciences Ireland UC | Hydrobromide salt of an anti-hiv compound |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
CA2674178C (en) | 2006-12-29 | 2015-11-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 6-substituted pyrimidines |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
EP2212298B1 (en) * | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US20090196890A1 (en) * | 2007-12-17 | 2009-08-06 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CA2723961C (en) | 2008-05-21 | 2017-03-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
BRPI0914682B8 (pt) | 2008-06-27 | 2021-05-25 | Avila Therapeutics Inc | compostos de heteroarila e composições compreendendo os referidos compostos |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
CN102369009B (zh) | 2009-03-30 | 2014-04-30 | 泰博特克药品公司 | 依曲韦林和烟酰胺的共晶体 |
CN102482277B (zh) | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
WO2010131118A2 (en) * | 2009-05-12 | 2010-11-18 | Pliva Hrvatska D.O.O. | Polymorphs of etravirine and processes for preparation thereof |
EP2342186B1 (en) | 2009-06-22 | 2014-09-17 | Emcure Pharmaceuticals Limited | Process for synthesis of etravirine |
US8153790B2 (en) | 2009-07-27 | 2012-04-10 | Krizmanic Irena | Process for the preparation and purification of etravirine and intermediates thereof |
GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
WO2012001695A1 (en) | 2010-06-28 | 2012-01-05 | Hetero Research Foundation | A process for etra virine intermediate and polymorphs of etravirine |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
AU2011305525B2 (en) | 2010-09-22 | 2016-08-18 | Arena Pharmaceuticals, Inc. | Modulators of the GPR119 receptor and the treatment of disorders related thereto |
BR112013010564B1 (pt) | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
ES2665013T3 (es) | 2010-11-10 | 2018-04-24 | Celgene Car Llc | Inhibidores de EGFR selectivos de mutante y usos de los mismos |
HUE046617T2 (hu) | 2010-11-10 | 2020-03-30 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
PL2702045T3 (pl) | 2011-04-26 | 2018-04-30 | Mylan Laboratories Ltd. | Nowy sposób sporządzania Etrawiryny |
CN103501612B (zh) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物 |
WO2012170647A1 (en) * | 2011-06-09 | 2012-12-13 | Assia Chemical Industriew Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
ES2690971T3 (es) | 2011-08-23 | 2018-11-23 | Asana Biosciences, Llc | Compuestos pirimido-piridazinona y uso de los mismos |
WO2013059572A1 (en) | 2011-10-19 | 2013-04-25 | Assia Chemical Industries Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
WO2013109354A2 (en) * | 2011-12-07 | 2013-07-25 | Texas Southern University | Etravirine formulations and uses thereof |
EP2825042B1 (en) | 2012-03-15 | 2018-08-01 | Celgene CAR LLC | Salts of an epidermal growth factor receptor kinase inhibitor |
BR112014022789B1 (pt) | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
US20150336900A1 (en) * | 2012-10-29 | 2015-11-26 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the Synthesis of Etravirine and Its Intermediates |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
MX2015007945A (es) | 2012-12-21 | 2016-02-16 | Verlyx Pharma Inc | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
CN104926829A (zh) * | 2015-06-08 | 2015-09-23 | 山东大学 | 一种噻吩并嘧啶类衍生物及其制备方法和应用 |
ES2929526T3 (es) | 2015-06-22 | 2022-11-29 | Arena Pharm Inc | Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1 |
CN110066273A (zh) * | 2019-06-05 | 2019-07-30 | 山东大学 | 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
CN111217833B (zh) * | 2020-02-21 | 2021-03-16 | 山东大学 | 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用 |
CN111875548A (zh) * | 2020-07-16 | 2020-11-03 | 山东大学 | 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041512A1 (en) * | 1997-03-14 | 1998-09-24 | Celltech Therapeutics Limited | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
EP0945443A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US4659363A (en) * | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
US4694009A (en) * | 1984-06-25 | 1987-09-15 | Ciba-Geigy Corporation | Pesticidal compositions |
DE68918804T2 (de) | 1988-03-31 | 1995-02-23 | Mitsubishi Chem Ind | Acyclische 6-substituierte pyrimidin nukleosid-abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten. |
JPH02308248A (ja) | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
JP2895680B2 (ja) * | 1992-07-08 | 1999-05-24 | シャープ株式会社 | 磁気ヘッドおよびその製造方法 |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
HUP9900730A3 (en) | 1995-11-23 | 2001-04-28 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
KR100219922B1 (ko) * | 1996-05-16 | 1999-09-01 | 이서봉 | 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법 |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
DE29704863U1 (de) * | 1997-03-17 | 1997-05-22 | Ges Innenhochdruckverfahren | Achsschwinge |
CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
EP0945442A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
DE69943247D1 (de) * | 1998-03-27 | 2011-04-14 | Janssen Pharmaceutica Nv | HIV hemmende Pyrimidin Derivate |
OA11674A (en) * | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
DK1282607T3 (en) * | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
-
1999
- 1999-09-24 OA OA1200100113A patent/OA11674A/en unknown
- 1999-09-24 SK SK603-2001A patent/SK287269B6/sk active Protection Beyond IP Right Term
- 1999-09-24 CA CA002350801A patent/CA2350801C/en not_active Expired - Lifetime
- 1999-09-24 AP APAP/P/2001/002121A patent/AP1683A/en active
- 1999-09-24 EE EEP200100252A patent/EE05086B1/xx active Protection Beyond IP Right Term
- 1999-09-24 EA EA200100536A patent/EA004049B1/ru active IP Right Revival
- 1999-09-24 IL IL14302399A patent/IL143023A0/xx active Protection Beyond IP Right Term
- 1999-09-24 AU AU62008/99A patent/AU762523C/en not_active Revoked
- 1999-09-24 SK SK5012-2009A patent/SK287270B6/sk not_active IP Right Cessation
- 1999-09-24 TR TR2001/01306T patent/TR200101306T2/xx unknown
- 1999-09-24 HU HU1100091A patent/HU230394B1/hu unknown
- 1999-09-24 BR BRPI9915552A patent/BRPI9915552B8/pt not_active IP Right Cessation
- 1999-09-24 CN CNB998119180A patent/CN1214013C/zh not_active Expired - Lifetime
- 1999-09-24 UA UA2001042857A patent/UA70966C2/uk unknown
- 1999-09-24 KR KR1020017003576A patent/KR100658489B1/ko active IP Right Grant
- 1999-09-24 HU HU0104177A patent/HU227453B1/hu active Protection Beyond IP Right Term
- 1999-09-24 ID IDW00200101015A patent/ID28376A/id unknown
- 1999-09-24 JP JP2000581005A patent/JP3635238B2/ja not_active Expired - Lifetime
- 1999-09-24 WO PCT/EP1999/007417 patent/WO2000027825A1/en active Application Filing
- 1999-09-24 NZ NZ511116A patent/NZ511116A/en not_active IP Right Cessation
- 1999-09-24 PL PL347586A patent/PL204427B1/pl unknown
- 1999-09-24 CZ CZ20011533A patent/CZ301367B6/cs not_active IP Right Cessation
- 1999-11-01 AT AT02018455T patent/ATE455107T1/de not_active IP Right Cessation
- 1999-11-01 AT AT99203590T patent/ATE233740T1/de active
- 1999-11-01 EP EP99203590A patent/EP1002795B1/en not_active Expired - Lifetime
- 1999-11-01 ES ES99203590T patent/ES2193664T3/es not_active Expired - Lifetime
- 1999-11-01 DE DE69905683T patent/DE69905683T2/de not_active Expired - Lifetime
- 1999-11-01 ES ES02018455T patent/ES2338760T3/es not_active Expired - Lifetime
- 1999-11-01 SI SI9930275T patent/SI1002795T1/xx unknown
- 1999-11-01 EP EP02018455A patent/EP1270560B1/en not_active Expired - Lifetime
- 1999-11-01 PT PT99203590T patent/PT1002795E/pt unknown
- 1999-11-01 DE DE122009000003C patent/DE122009000003I1/de active Pending
- 1999-11-01 DE DE69941934T patent/DE69941934D1/de not_active Expired - Lifetime
- 1999-11-01 US US09/430,966 patent/US6878717B2/en not_active Expired - Lifetime
- 1999-11-01 DK DK99203590T patent/DK1002795T3/da active
- 1999-11-05 MY MYPI99004805A patent/MY121108A/en unknown
- 1999-11-09 AR ARP990105680A patent/AR024227A1/es active IP Right Grant
- 1999-12-23 TW TW088119614A patent/TWI238161B/zh not_active IP Right Cessation
-
2000
- 2000-07-26 HK HK00104633A patent/HK1025330A1/xx not_active IP Right Cessation
-
2001
- 2001-03-07 HR HRP20010161AA patent/HRP20010161B9/hr not_active IP Right Cessation
- 2001-04-04 NO NO20011696A patent/NO318801B1/no not_active IP Right Cessation
- 2001-04-06 BG BG105418A patent/BG65103B1/bg unknown
- 2001-05-09 ZA ZA200103769A patent/ZA200103769B/en unknown
-
2003
- 2003-02-14 HK HK03101063.7A patent/HK1048817B/zh not_active IP Right Cessation
- 2003-08-05 US US10/634,682 patent/US7037917B2/en not_active Expired - Lifetime
-
2005
- 2005-07-28 IL IL169949A patent/IL169949A/en not_active IP Right Cessation
- 2005-08-16 US US11/204,513 patent/US20050288278A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/930,835 patent/US8003789B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 HR HRP20080359AA patent/HRP20080359B1/hr not_active IP Right Cessation
- 2008-12-03 LT LTPA2008016C patent/LTC1002795I2/lt unknown
- 2008-12-10 CY CY2008021C patent/CY2008021I2/el unknown
-
2009
- 2009-01-13 NL NL300373C patent/NL300373I2/nl unknown
- 2009-01-22 FR FR09C0004C patent/FR09C0004I2/fr active Active
- 2009-02-18 LU LU91528C patent/LU91528I2/fr unknown
- 2009-02-23 NO NO2009003C patent/NO2009003I2/no unknown
-
2011
- 2011-02-18 AU AU2011200708A patent/AU2011200708A1/en active Pending
- 2011-07-06 US US13/177,188 patent/US8530655B2/en not_active Expired - Fee Related
-
2021
- 2021-03-29 NO NO2021015C patent/NO2021015I1/no unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998041512A1 (en) * | 1997-03-14 | 1998-09-24 | Celltech Therapeutics Limited | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
EP0945443A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20080359B1 (hr) | PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a | |
EA200400304A1 (ru) | Производные пиримидина, ингибирующие вич | |
HRP20050688A2 (en) | Pyrimidine derivatives for the prevention of hiv infection | |
MEP13408A (en) | Cdk inhibiting pyrimidines, production thereof and their use as medicaments | |
DK0553191T3 (da) | Pyridin- og pyridin-N-oxidderivater af diarylmethylpiperidiner eller -piperaziner, præparater og an vendelse deraf | |
TR200002760T2 (tr) | HIV engelleyici pirimidin türevleri | |
HUP0300894A2 (hu) | Szubsztituált béta-karbolinok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
HRP20040097B1 (hr) | 2-amino-4,5-trisupstituirani derivati tiazolila | |
BR0214876A (pt) | Formas de sal de e-2-metóxi-n-(3-(4-(3-metil-piridin-3-ilóxi)-fenilamino)qui nazolin-6-il)-alil)-acetamida, suas preparações e uso dos mesmos contra o câncer | |
MY129224A (en) | 4-phenyl-pyridine derivatives | |
TR199701647A2 (xx) | �kame edilmi� purin t�revleri,bunlar�n imalat usul� | |
ATE21900T1 (de) | Pyrimidinonderivate und diese enthaltende pharmazeutische zusammenstellungen. | |
CY1105596T1 (el) | Παραγωγα 2,4-δισυποκατεστημενης τριαζινης με δραση κατα του hiv | |
AR038824A1 (es) | Composiciones de medicamentos que, junto a agentes colinergicos, contienen compuestos heterociclicos | |
HUP9904173A2 (hu) | Gyógyszerkészítmény vírusos betegségek kezelésére | |
ATE500231T1 (de) | Hiv hemmende pyrimidin derivate | |
TR200200111T2 (tr) | Neoplazmalar için terapötik ve profilaktik maddeler | |
CY1125571T1 (el) | Πυριμιδινες που αναστελλουν τον πολλαπλασιασμο toy hiv | |
DOP2004001030A (es) | Heterociclos amino de seis eslabones que contienen nitrogeno sustituido como antagonistas del receptor 1 vainilloide para tratamiento del dolor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20180814 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20190924 |